MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apt.70386

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2025

Cost-Utility Analysis of Biomarker-Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B.

Saeoui Tanat, Kositamongkol Chayanis, Chantrakul Ratthanan, Sripongpun Pimsiri, Chamroonkul Naichaya, Kongkamol Chanon, Phisalprapa Pochamana, Kaewdech Apichat

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The standard surveillance for hepatocellular carcinoma (HCC) involves ultrasound (USG) with alpha-fetoprotein (AFP) every 6 months. However, limitations, such as restricted access, radiologist shortages, and uncertain cost-effectiveness, persist.

AIMS: We assessed the cost-effectiveness of traditional and biomarker-based HCC surveillance strategies in patients with chronic hepatitis B (CHB).

METHODS

A Markov model simulated a cohort of patients with CHB to evaluate the cost-effectiveness of various surveillance strategies: USG + AFP, GAAD, GALAD, ASAP, and no surveillance. Input parameters were sourced from literature and Thai healthcare data. The analysis adopted a societal perspective and lifetime horizon, calculating incremental cost-effectiveness ratios (ICERs) in Thai Baht (THB) per quality-adjusted life year (QALY) gained. Sensitivity analyses assessed robustness.

RESULTS

ASAP every 6 months was the most cost-effective strategy, with ICERs of 102,443 THB (~2957 USD) per QALY versus ASAP every 12 months and 76,447 THB (~2207 USD) per QALY versus no surveillance. Although GAAD and GALAD every 6 months achieved similar QALYs, they were dominated due to higher costs. Annual surveillance improved cost-effectiveness but remained inferior to ASAP every 6 months. USG + AFP every 6 months incurred the highest lifetime cost (166,253 THB, ~4800 USD). Sensitivity analyses confirmed the robustness of ASAP every 6 months, with key drivers including biomarker costs, HCC stage utilities, and incidence rates.

CONCLUSIONS

ASAP every 6 months is the most cost-effective HCC surveillance strategy for patients with CHB and may be particularly suitable for resource-limited settings. Biomarker-based surveillance should be prioritised to improve outcomes and optimise resource use.

Для цитирования: Saeoui Tanat, Kositamongkol Chayanis, Chantrakul Ratthanan, Sripongpun Pimsiri, Chamroonkul Naichaya, Kongkamol Chanon, Phisalprapa Pochamana, Kaewdech Apichat. Cost-Utility Analysis of Biomarker-Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B.. Alimentary pharmacology & therapeutics. 2025. DOI: 10.1111/apt.70386.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.